BRUSSELS (Reuters) - Belgian biotechnology firm TiGenix has recruited enough patients to start a mid-stage trial for its stem cell-based treatment for rheumatoid arthritis, it said on Wednesday. "This is the most advanced stem cell therapy trial in rheumatoid arthritis in the world, and completing the enrolment on time confirms our leadership position in the field," said chief executive Eduardo Bravo in a statement. "We anticipate reporting the results of the study no later than April 2013. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment